PTI vs. FBIO, XLO, VIRX, BCTX, UNCY, VYNE, CASI, THTX, ACXP, and IPA
Should you be buying Proteostasis Therapeutics stock or one of its competitors? The main competitors of Proteostasis Therapeutics include Fortress Biotech (FBIO), Xilio Therapeutics (XLO), Viracta Therapeutics (VIRX), BriaCell Therapeutics (BCTX), Unicycive Therapeutics (UNCY), VYNE Therapeutics (VYNE), CASI Pharmaceuticals (CASI), Theratechnologies (THTX), Acurx Pharmaceuticals (ACXP), and ImmunoPrecise Antibodies (IPA). These companies are all part of the "medical" sector.
Proteostasis Therapeutics (NASDAQ:PTI) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, community ranking, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.
Fortress Biotech has a consensus target price of $30.00, suggesting a potential upside of 1,644.19%. Given Fortress Biotech's higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Proteostasis Therapeutics.
Proteostasis Therapeutics has higher earnings, but lower revenue than Fortress Biotech. Proteostasis Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.
Fortress Biotech received 6 more outperform votes than Proteostasis Therapeutics when rated by MarketBeat users. Likewise, 64.86% of users gave Fortress Biotech an outperform vote while only 59.03% of users gave Proteostasis Therapeutics an outperform vote.
16.6% of Proteostasis Therapeutics shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 4.8% of Proteostasis Therapeutics shares are held by company insiders. Comparatively, 33.4% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Proteostasis Therapeutics has a net margin of 0.00% compared to Fortress Biotech's net margin of -74.12%. Proteostasis Therapeutics' return on equity of -75.39% beat Fortress Biotech's return on equity.
Proteostasis Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500.
In the previous week, Proteostasis Therapeutics and Proteostasis Therapeutics both had 1 articles in the media. Proteostasis Therapeutics' average media sentiment score of 0.00 equaled Fortress Biotech'saverage media sentiment score.
Summary
Fortress Biotech beats Proteostasis Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Proteostasis Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Proteostasis Therapeutics Competitors List
Related Companies and Tools
